Search

Your search keyword '"Feagan, B"' showing total 699 results

Search Constraints

Start Over You searched for: Author "Feagan, B" Remove constraint Author: "Feagan, B"
699 results on '"Feagan, B"'

Search Results

153. OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study

157. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

160. An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease

162. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

164. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

165. Reliability of histologic assessment in patients with eosinophilic oesophagitis

173. P544 Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study

175. P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies

178. Ustekinumab as induction and maintenance therapy for Crohn's disease

180. LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 2 YEARS

181. The development of a magnetic resonance imaging index for fistulising Crohn's disease

183. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis

186. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease

188. Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel

190. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy

191. OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1

193. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A’Human MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2: Abstract OC-007 Table 1

194. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis

195. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE):Determining Therapeutic Goals for Treat-to-Target

196. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health

197. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials

198. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

199. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

Catalog

Books, media, physical & digital resources